Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
June 30, 2020 updated by: Baylor Research Institute
Do Sleeve Gastrectomies Result in Improved Gastric Emptying and Thus Improved Symptoms in Patients With Diabetic Gastroparesis?
The purpose of this registry is to evaluate if sleeve gastrectomy surgery will help with symptoms of delayed gastric emptying for patients suffering from diabetic gastroparesis.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This is a prospective registry enrolling patients with an established diagnosis of diabetic gastroparesis and interested in receiving a sleeve gastrectomy for weight loss.
An often intentional outcome of sleeve gastrectomy is an increase in gastric emptying.
The relationship between how beneficial this outcome could be for diabetic gastroparesis patients suffering from delayed gastric emptying is not very well established.
The purpose of this study is to find out if sleeve gastrectomy surgery will also help with symptoms of delayed gastric emptying.
This study involves completing the Gastroparesis Cardinal Symptom Index questionnaire before your weight loss surgery and after surgery at the following time points; 30 days, 3 months, 6 months, and 12 months.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75231
- Baylor Weight Loss Surgery Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study group will be patients with diabetic gastroparesis who qualify for bariatric weight loss surgery (BMI >35, insurance/medicare bariatric coverage).
These patients are referred by gastroenterologists and/or endocrinologists with established diagnosis of diabetic gastroparesis confirmed via delayed gastric emptying on scintigraphy.
All available treatment options will be discussed with every qualifying patient.
Patients opting for sleeve gastrectomy will be invited to participate in the registry.
Description
Inclusion Criteria:
- Age 18 years and above
- BMI > 35
- Diagnosis of diabetic gastroparesis as confirmed via scintigraphy
- Subject opting to undergo sleeve gastrectomy
Exclusion Criteria:
- Any previous weight loss surgery or prior gastrectomies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Examine gastroparesis symptoms
Time Frame: 1 year
|
Administer the Gastroparesis Cardinal Symptom Index (GCSI).
The GCSI consists of three subscales: (1) Nausea/vomiting, (2) Fullness/early satiety, and (3) Bloating/distention.
The average score is calculated from these three subscales with higher scores indicating greater symptom severity.
The symptoms are rated on a scale from 0-5 with zero reflecting no symptoms and 5 indicating very severe symptoms.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Daniel Davis, DO, Baylor Scott & White, Baylor University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 25, 2017
Primary Completion (ANTICIPATED)
December 31, 2020
Study Completion (ANTICIPATED)
December 31, 2020
Study Registration Dates
First Submitted
December 13, 2017
First Submitted That Met QC Criteria
December 13, 2017
First Posted (ACTUAL)
December 18, 2017
Study Record Updates
Last Update Posted (ACTUAL)
July 2, 2020
Last Update Submitted That Met QC Criteria
June 30, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 017-370
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.